Congestive heart failure disease management program: 1-Year population experience from a tertiary center heart failure registry in Saudi Arabia  by Salem, Khal et al.
P.O. Box 2925 Riyadh – 11461KSA
Tel: +966 1 2520088 ext 40151
Fax: +966 1 2520718
Email: sha@sha.org.sa
URL: www.sha.org.sa
FU
LL
 L
EN
G
TH
 A
RT
IC
LE
Disclosure: Authors have nothing to disclose with regard to commercial
support
Received 4 March 2016; revised 4 July 2016; accepted 15 July 2016.
⇑ Corresponding author at: Cardiac Rehabilitation Program, King
Abdullah Medical City (KAMC), Muzdalifah Road, Cardiology Depart-
ment, KAMC, 4th floor, Makkah 21955, Saudi Arabia.
E-mail address: cardio1@live.ca (K. Salem).Congestive heart failure disease management
program: 1-Year population experience from a
tertiary center heart failure registry in
Saudi Arabia1016–7315  2016 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access article under th
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Peer review under responsibility of King Saud University.
URL: www.ksu.edu.sa
http://dx.doi.org/10.1016/j.jsha.2016.07.002 Production and hosting by Elsevier
Please cite this article in press as: Salem K. et al., Congestive heart failure disease management program: 1-Year population experience
tertiary center heart failure registry in Saudi Arabia, J Saudi Heart Assoc (2016), http://dx.doi.org/10.1016/j.jsha.2016.07.002Khal Salem a,⇑, Dania Fallata a, Maha ElSebaie a,b, Ahmad Montasser a,
Khaled ElGedamy a, Osama ElKhateeb aaCardiac Centre, King Abdullah Medical City (KAMC), Makkah
bZagazig University, Cairo
a Saudi Arabia
b EgyptAims: We aimed to evaluate congestive heart failure (CHF) multidisciplinary disease management program
(DMProg) impact on mortality, readmission rates, length of stay (LOS), and gender health characteristics.
Methods and results: This was a quasi-observational, pre- and post-trial with a parallel nonequivalent group. We
enrolled 174 inpatients having CHF with reduced ejection fraction and New York Heart Association (NYHA) Class
II–IV, and a total of 197 hospital admissions. A comparative follow-up was performed from 15 December 2014 to 15
December 2015. Among 197 consecutive hospital admissions, 76 (39%) were included in the preintervention or usual
care group and 121 (61%) were assigned to the postintervention group. After 1 year, in comparison with the prein-
tervention group, the postintervention group had shorter average LOS in days (7.6 days vs. 11.1 days, p < 0.002),
lower 1-year readmission rate (36% vs. 57%, p < 0.003), and lower in-house mortality (1.6% vs. 7.8%, p = 0.03), but sim-
ilar baseline mortality scores (38.2 vs. 38.6, p = 0.7), 30-day and 90-day readmission rates (15% vs. 18.3%, p = 0.62 and
27.6% vs. 30%, p = 0.65), and 30-day readmission risk score (24.9% vs. 26.2%, p = 0.09). By regression analysis, the
DMProg intervention was an independent factor for 1-year readmission reduction (p = 0.001). Kaplan–Meier survival
analysis favored the postintervention group (log-rank, p < 0.001).
Conclusion: DMProg significantly decreased 1-year readmission rates, LOS, and in-house mortality.
 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Abbreviations
NYHA New York Heart Association
DMProg disease management program
CHF congestive heart failure
GDMT guideline-directed medial therapy
HFrEF heart failure with reduced ejection fraction
Mak-HFR Makkah heart failure registry
DAMA discharge against medical advice
LOS length of stay
BB beta blocker
ACEI angiotensin converting enzyme inhibitor
ARB angiotensin receptor blockers
MRA menieralo-corticoid receptor antagonist
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Congestive heart failure (CHF) is one of theleading causes of hospitalization among the
elderly population of Europe and North America.
However, information on the developmental
strategies, components, and outcomes in the Mid-
dle Eastern population is limited [1] and has been
traditionally classified under the ‘others’
subgroup.
In industrialized countries, CHF utilized 1–2% of
the total health expenditure and exceeded the
combined costs of acute coronary syndrome and
cancer [2]. It has higher mortality rates than AIDS
and all types of cancer [3], lower median survival
in males (1.7 years) than in females (3.2 years),
and 30–50% of 6-month readmission rate [3,4].
Over the past 20 years, best CHF management
practices have evolved into the establishment of
a multidisciplinary team, development of an out-
patient clinic, performance of a 72-hour postdis-
charge phone call, implementation of different
templates for standardized clinical pathways
[3,5,6], and introduction of guideline-directed
medial therapy (GDMT) [3,4,7]. GDMT refers pri-
marily to Class I-recommended medications,
including angiotensin-converting enzyme inhibi-
tors (ACEI) or angiotensin-2 receptor blockers
(ARBs), beta blockers (BB), diuretics, aldosterone,
and in selected patients, hydralazine–nitrate com-
bination. Bisoprolol, carvedilol, and extended-
release metoprolol are the mainstays of pharma-
cologic BB therapy for heart failure with reduced
ejection fraction (HFrEF). Multidisciplinary team
approach programs have improved functional sta-
tus, decreased 1-year rehospitalization from 57%
to 36%, shortened length of stay (LOS), and
emphasized compliance [8–10].
This study aimed to evaluate the impact of a
heart failure disease management program
(DMProg) model on mortality; readmission rates
at 30 days, 90 days, and 1 year; LOS; gender-
based response and characteristics in a Middle
Eastern population. In addition, we aimed to pro-
pose a new program framework using prospective
data analysis from the Makkah Heart Failure Reg-
istry (Mak-HFR).Materials and methods
Study design
This was a quasi-observational, pre- and post-
trial with a parallel nonequivalent group. We
enrolled 174 inpatients having CHF with reducedPlease cite this article in press as: Salem K. et al., Congestive heart failure
tertiary center heart failure registry in Saudi Arabia, J Saudi Heart Assocejection fraction and New York Heart Association
(NYHA) Class II–IV, and a total of 197 hospital
admissions. Starting 15 December 2014, we
enrolled consecutive patients admitted to the car-
diac department. Inclusion criteria were HFrEF of
40–45% or less, based on echocardiographic
report; age range of 18–70 years and NYHA func-
tional Class II–IV. The exclusion criteria included
cardiogenic shock; mechanical ventilatory sup-
port; unstable coronary artery disease; acute
myocarditis; planned cardiac surgery, including
transplantation; severe aortic stenosis; and signif-
icant comorbid conditions, such as malignancy
and severe disabling obstructive lung disease.
We followed-up the clinical course of the initial
76 (usual care group) and 121 (intervention group)
hospital admissions from the time of referral until
discharge. LOS was evaluated and readmission
root cause analysis was performed. Data were uti-
lized to develop customized clinical pathway and
standardized tools. Performance outcome mea-
sures and control charts were monitored on the
next 121 patients admitted to the hospital (inter-
vention group).
We calculated the predicted mortality score
using the Get with the guidelines-HF (GWTG-
HF) risk model and the 30-day readmission risk
score for heart failure online calculator; both are
advocated by the American Heart Association
(AHA) [11].
The program structure consisted of the follow-
ing three main components: (1) an executive spon-
sor that was aligned with the strategic direction of
the organization and allocated resources; (2) a
nurse specialist coordinator of care and a well-
trained, high functioning team that applied the
best clinical heart failure practice tools; and (3) a
cardiologist who served as the chairman of the
program.disease management program: 1-Year population experience from a
(2016), http://dx.doi.org/10.1016/j.jsha.2016.07.002
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The core intervention components comprised 4-
day clinical pathway, standardized tools, 72-hour
postdischarge phone call, and early postdischarge
appointment in a one-site/nurse/physician heart
failure clinic. We monitored the 4-day cumulative
defects of a two-component clinical pathway. The
pathway functioned as a monitoring checklist and
was not part of the medical record. The first path-
way component was task-directed and included
expected outcomes, goals, activity level, as well
as diagnostic, nutritional, therapeutic, educa-
tional, and transitional care assessment and
needs. The second clinical pathway component
included team member role items. The pathway
checklist was used only for the first 4 days of hos-
pitalization, after which monitoring was based on
‘increased LOS root cause analysis’ and an action
plan. Root cause analysis was performed for every
readmitted patient. The nurse coordinator used a
standardized six-step checklist during daily
rounds and measured the GWTG-HF risk model,
which was advocated by the AHA to predict in-
hospital mortality [12,13] and the heart failure
readmission risk score [14].
Patient education was part of the intervention
and focused on symptom recognition, ideal weight
definition, and medication reconciliation. Target-
ing a total of 60 minutes of education throughout
hospitalization, we used interactive workbooks
and teach-back techniques. Later on in the study,
we added an individualized A4-sized take-home
action plan for each patient at Grade 4 education
level.
Transition of care was done through a 72-hour
postdischarge phone call that was performed by
the nurse coordinator, followed by arranging for
appointment in the heart function clinic 1–2 weeks
after discharge. The expected outcomes from
phone calls were reinforcement of self-
management and recognition of worsening symp-
toms by the patient; screening postdischarge
heath status and directing patients towards con-
tinuation of home stay, and early scheduling of
appointment at the heart failure clinic or direct
admission to the hospital, in case of unmanage-
able deterioration. In this study, we chose not to
use patient self-treatment with diuretic sliding
scale as part of the education curriculum or transi-
tion of care.
One-nurse/one-physician/one-site clinic (triple-
one clinic)
Each patient in the intervention group was
invited to the heart failure clinic 1–2 weeks afterPlease cite this article in press as: Salem K. et al., Congestive heart failure
tertiary center heart failure registry in Saudi Arabia, J Saudi Heart Assocdischarge. The clinic coordinator performed as-
needed consultation with the rest of the team that
included a pharmacist, a dietician, an educator,
and a psychologist. The physician and nurse
reviewed the medications and revised the patient
logbook. The outputs of the clinic visit were refer-
ral back to the primary physician, follow-up if
readjustment of medications was needed, empha-
sis on self-management skills, and reinforcement
of education.Statistical analysis
Data analysis was performed using the Minitab
statistical analysis software version 17.2.1 (Minitab
company, Pennsylvania, USA). Statistical signifi-
cance was determined by the Student t test, with
a two-sided p value < 0.05; one-sided t-test and
upper limit of confidence interval were used to
analyze the in-house mortality data. The non-
normally distributed data on LOS were trans-
formed using the Box–Cox plot methodology and
were then analyzed by the Student t test. Analysis
of variance was used to assess the effects of the
intervention. We used backward stepwise multi-
ple linear regression analysis to identify the deter-
minants of LOS variation. In this study, we
referred to the combined in-house mortality and
30-day readmissions as the ‘program 30-day
event-free period’.Results and discussion
Outcome measures
In the Mak-HFR, CHF represented 10% of all
cardiac hospital admissions; 80% of them were
HFrEF. We calculated the predicted mortality
score using the GWTG-HF risk model that has
been provided by the AHA; GWTG-HF risk model
predicts in-house mortality using a score ranging
from 0 to100 [13]. We found a clear mortality ben-
efit in the intervention group. The calculated
expected mortality based on average mortality
score was 38.5 versus 38.2 points (equivalent to
1–5% of the expected mortality rate) in the control
and intervention groups, respectively; whereas
the actual mortality rate in the preintervention
group was higher (7.8%), compared with 1.6% in
the postintervention group. Readmission rates
had a nonsignificant decreasing trend after
30 days (from 18% to 15%; p = 0.62) and 90 days
(from 30% to 27%; p = 0.65). However, compared
with the preintervention group, the postinterven-
tion group had lower 1-year readmission rate (36%
vs. 57%; p < 0.003), shorter LOS (11.7 vs. 7.6 days;disease management program: 1-Year population experience from a
(2016), http://dx.doi.org/10.1016/j.jsha.2016.07.002
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against medical advice (DAMA) (0% vs. 4.4%;
p < 0.001).
The top reasons for longer LOS in the usual care
group were delayed symptomatic improvement
(30%), absence of strict daily weight
measurements (15.4%), and delayed follow-up on
consultation requests (15%). However, the postin-
tervention group had comorbidities (17.9%), drai-
nage requirements (11.4%), and submaximal
medication dosage (10.3%). The LOS regression
analysis model confirmed that the DMProg
intervention was one of the three independent
factors of shortening LOS (p = 0.008); the other
two factors were the absence of atrial fibrillation
(p = 0.001) and the use of furosemide diuretic
(p = 0.013).Number of admitted HFrE
Admissions based on the enr
Pre intervention 
group from 
January to 
March 2015  
(n =76)  
Post intervention 
Group from 
April to 
December 2015 
(n = 121)  
Admissions with an ICD 9 diagnosis of congest
HFpEF (n 
Cardiac admission to the cardiac ward, CCU,
Age 18–70 years, symptomatic heart 
failure (NYHA Class II–IV), and left 
ventricular ejection fraction of 40%, 
as measured by echocardiography  
Figure 1. Patient enrolment flow chart. CCU = coronary care unit; ICD =
ejection fraction; HFpEF = heart failure with preserved ejection fraction; N
Please cite this article in press as: Salem K. et al., Congestive heart failure
tertiary center heart failure registry in Saudi Arabia, J Saudi Heart AssocDischarge medications
Upon discharge from the hospital, following
medications were administered to the patients:
ACEI (47.7%), hydralazine (26%), BBs (86%),
spironolactone (48%), furosemide (81%), nitrates
(38%), ARB (11.7%), and digoxin (7.6%). There
was a nonstatistically significant increased utiliza-
tion of ACEI, BB, furosemide, and spironolactone,
but there was no impact on hydralazine, nitrate, or
ARB (p > 0.05 for all variables). The number of
patients on hydralazine and nitrate combination
was 22.8%. We performed a subgroup analysis
comparing ACEI or ARB with combined hydrala-
zine and nitrate treatment, in addition to BBs. In
both arms, there was no difference in the test of
equal variance of a combined 30-day readmission
and in-house mortality event free survivalF patients (n = 292) 
olment criteria (n = 197) 
ive heart failure, including both HFrEF and 
= 362) 
 chest pain unit, day care unit (n = 3460)
Cardiogenic shock; mechanical ventilatory
support; unstable coronary artery disease; 
acute myocarditis; planned cardiac surgery, 
including transplantation; severe aortic 
stenosis; significant co-morbid conditions, 
such as malignancy or severe obstructive 
lung disease; and age <18 and >70 years
Exclusion group (n = 95) 
implantable cardiac defibrillator; HFrEF = heart failure with reduced
YHA = New York Heart Association.
disease management program: 1-Year population experience from a
(2016), http://dx.doi.org/10.1016/j.jsha.2016.07.002
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nitrate/BB groups (p = 0.857; Fig. 1). That men-
tioned, the interpretation was challenged by the
following evidence-based target average daily
doses: ACEI (perindopril, 3.7 mg), BB (bisoprolol,
3.6 mg; carvedilol, 12.8 mg), ARBs (valsartan
77.5 mg; irbesartan, 214 mg), furosemide
(63.1 mg), spironolactone (18.9 mg), hydralazine
(96.6 mg), dinitrate (35 mg), and digoxin
(0.112 mg).
The discharge medications in this population
were characterized by the use of ACEI (47%),
hydralazine (26%), nitrates (38%), and a combina-
tion of hydralazine and nitrates (22%). The use of
ARBs (11.9%) and BBs (86%) was as expected.
72-hour phone call
Only 63% (47 of 103) of patients answered the 3-
day postdischarge phone calls; 67% of those who
answered felt well and followed instructions,
17% had CHF symptoms, 7% had nonlife-
threatening bleeding complications, 4% did not
follow instructions, and 4% required direct hospi-
tal admission. Of the eight CHF symptoms that
were reported, six (75%) were successfully man-
aged by phone, whereas two (25%) required out-
patient consultation the following day at the
triple-one clinic. The low reply rate of the phone
call was a challenge of complex nature. After dis-
charge, each patient received two 72-hour phone
calls during the weekday working hours. We used
a ‘‘no-reply’’ hospital owned dedicated landline.
The contact numbers that were available on
record do not necessarily belong to patients them-
selves; the majority belonged to the family-
selected next of kin or the decision-making indi-
viduals, and subsequently direct talking to some
of the patients failed. Moreover, some patients
were not willing to answer a nonfamiliar private
phone number. Moreover, the sleep–awake cycle
of the patient somehow interfered with the ability
to designate proper calling time during the 8:00
AM to 16:00 PM weekday hours. The authors’ cur-
rent opinion is that phone calls are resource-
intensive, difficult to measure, and of unclear
cost-effectiveness impact; moreover, further data
analysis is required when we achieve a larger
sample size.
Cost effectiveness
Although evaluation of cost effectiveness was
not an aim of the study, the cost savings might
be due to the reduction of annual hospital occu-
pancy and a 15% average reduction of readmis-
sion rate and hospitalization. However, the costPlease cite this article in press as: Salem K. et al., Congestive heart failure
tertiary center heart failure registry in Saudi Arabia, J Saudi Heart Assoceffectiveness of this DMProg in the Middle East
warrants future research.
Lessons learned
In the Middle East, a literature review revealed a
30-day mortality of 5.3–9% (12). In this study,
HFrEF DMProg shortened LOS; decreased in-
house mortality and 1-year readmission rates;
did not negatively affect gender-specific health-
care disparity; did not improve the combined 30-
day and in-house mortality event rates; and may
result in cost saving through reduction of bed
occupancy and shortened LOS. The triple-one
heart failure clinic was an efficient and effective
model. Hydralazine and nitrate therapy may have
mortality and 30-day readmission benefits that
were not inferior to those of ACEI/ARB treatment.
The 2013 ACCF/AHA Heart Failure Guidelines
state the use of a combination of hydralazine
and isosorbide dinitrate as Class I (in combination
with ACEI) or Class IIa (if ACEI cannot be given)
recommendations for African Americans, but
there are no similar recommendations for the
Middle Eastern population. Further a large-scale,
randomized controlled trial is recommended.
Therefore, this study proposed a structural pro-
gram triad of: (1) executive sponsor; (2) coordina-
tor of care; and (3) a well-trained and properly
tooled cardiologist-led team as a valid framework
for a heart failure management program. This
model provided evidence on long-term, sustain-
able outcomes that exceeded the initial 30 days
of implementation.
This study demonstrated no statistically signifi-
cant improvement of the 30-day or 90-day read-
mission rates; however, there was improvement
of the 1-year readmission rate. We attributed this
positive long-term impact of the DMProg to the
expected enhanced education and self-
management skills the patients had acquired.
The initial 60-minute education during hospital-
ization, the quick symptom-recognition during
the phone calls, and the further reinforcement
that happened if the patients were readmitted
could be applied to the multidisciplinary team
performance also. Such a patient-
multidisciplinary team learning curve hypothesis
deserves further validation.
Strengths and limitations of the study
The study may shed some light on the charac-
teristics of a Middle Eastern ethnic group of CHF
patients who have traditionally been referred to
as part of the ‘others’ category in medical litera-
ture. In addition, it may open the field for devel-disease management program: 1-Year population experience from a
(2016), http://dx.doi.org/10.1016/j.jsha.2016.07.002
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ease management; and advocate the use of DAMA
as a patient experience performance indicator, a
statistical process control, and capability charts
that uses evidence-based customized tools.
The improvement in mortality from cardiac
death was probably overestimated because of
the small sample size and because the exclusion
criteria did not include active coronary artery dis-
ease, which may have resulted in unintentional
exclusion and different The International Classifi-
cation of Diseases-9 (ICD-9) coding. Moreover, the
80% of HFrEF representation was higher than
international norms, raising the possibility of
unintentional selection bias. The study pointed
out some areas of success, but it did not identify
the primary cause of process improvement. These
findings may suggest a multifactorial positive
impact of the program structure, the framework
triad, standardized tools, team approach method-
ology, human factors, and the implementation of
clinical pathways on the long term outcome of
the CHF disease management program. More-
over, the multidisciplinary team was extensively
involved in the outpatient management of the
enrolled patients and this may have contributed
to the more obvious 1-year outcomes compared
with the short-term outcome, and such a hypoth-
esized favorable impact of multidisciplinary out-
patient care on the long-term outcome would
need to be validated by further studies. Finally,
although the program resulted in increased use
of ACEI and BB, decreased use of hydralazine
and digoxin, and equivocal use of ARB, these
changes were statistically insignificant, indicating
that a program impact on the prescribing culture
of physicians may be an opportunity for
improvement.Acknowledgments
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